Global biopharmaceutical major AstraZeneca and Indian IT industry body Nasscom have joined hands to set up an accelerator programme to support Indian startups in healthcare space.





Headquartered in Cambridge, U.K. AstraZeneca has launched a strategic partnership with the Nasscom IoT Centre of Excellence to set up an accelerator programme to support Indian startups develop innovative solutions to non-communicable diseases (NCDs) care in India.






AstraZeneca also signed a Memorandum of Understanding with NASSCOM




AstraZeneca PLC Chairman of the Board Leif Johansson told PTI: “Best healthcare that can be provided and developed comes from cooperation across borders between industry, government and academia in a such way that we, with the help of technology, can provide a higher-quality service at a lower cost.” AstraZeneca is committed to strengthening innovation in healthcare in India, he added.





In a statement, Johansson said: “We are pleased to collaborate with the government, start-up eco-system and industry partners to achieve the shared vision of making meaningful interventions in improving the lives of patients impacted by non-communicable diseases in India.” Highlighting the Unnati initiative, Sweden’s Trade Commissioner to India Carsten Grönblad said: “Unnati is a model for co-innovation allowing industry, start-ups and the civil society to jointly develop solutions addressing global social needs.” This challenge calls for collaboration to implement early and remote screening as well as efficient AI-based patient management, he added.





NASSCOM – CoE IoT was launched as part of Government of India’s Digital India Initiative to help the country achieve a leadership role in the convergent areas of hardware and software. Under this collaboration, AstraZeneca and NASSCOM will incubate start-ups in bringing innovative and frugal solutions that can help in the management of NCDs. 





Source - Financial Express





Top Featured Image - WSJ.com


Advertisements

Post a Comment

أحدث أقدم
Like this content? Sign up for our daily newsletter to get latest updates.